EF Hutton Initiates Coverage On CARISMA Therapeutics with Buy Rating, Announces Price Target of $24
Portfolio Pulse from Benzinga Newsdesk
EF Hutton has initiated coverage on CARISMA Therapeutics with a Buy rating and set a price target of $24.
October 30, 2024 | 1:15 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
EF Hutton has initiated coverage on CARISMA Therapeutics with a Buy rating and a price target of $24, indicating a positive outlook for the stock.
The initiation of coverage with a Buy rating and a specific price target of $24 by EF Hutton suggests a positive sentiment towards CARISMA Therapeutics. This is likely to boost investor confidence and could lead to an increase in the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100